Family ties: Boehringer's first TV ad for Ofev leans on loved ones' connections to IPF

Boehringer spotlights an IPF patient's son in a new TV ad meant to encourage patients to consider their importance to family. (Boehringer)

In Boehringer Ingelheim’s first branded TV ad for its idiopathic pulmonary fibrosis treatment Ofev, the spotlight is not on the patient, but on a loved one. In ads begun last month, the son of an IPF patient narrates the commercial talking about his dad’s fight with IPF and how he inspires him.

The son, who is a boxer, says, “His IPF isn’t contagious, but the way he lives his life is. … Your battle for IPF isn’t just for you.”

Boehringer is shifting the focus to loved ones because its research found that patients with IPF who don’t fully understand the disease progression often choose not to treat their disease.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

RELATED: Boehringer Ingelheim's global IPF effort asks 'why wait?' for treatment in campaign aimed at doctors

“We want to change that and remind patients that they don’t fight IPF only for themselves, they also do it for the people they love,” Al Masucci, vice president of the IPF business unit at Boehringer, said in an email interview. “By choosing to treat IPF, patients can build memories and a legacy that they can pass on to their loved ones.”

The new campaign is currently only on TV, but it will expand to other media in the future, he said. Previous branded ads for Ofev have run in digital channels and on social media. Unbranded marketing has included patients and loved ones—such as an effort featuring former Yankees slugger Bernie Williams, whose father had IPF—primarily to drive awareness of the progressive lung disease.

RELATED: Boehringer, Minor League Baseball aim for bubble-blowing record to raise IPF awareness

The new campaign strikes a sentimental tone with its goal to “illustrate the most important reason for talking to their doctor about the right treatment plan—family. We want to remind patients that there is so much to live for," Masucci said.

The FDA first approved Ofev in October, 2014, the same day as competitor Esbriet from Roche, and the battle for market share has proved fierce ever since. Boehringer recorded sales of €531 million for the first six months of 2018, a currency-adjusted increase of 35%, the company said.

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.